Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 27, 2020SANTA BARBARA, Calif., Feb 27, 2020 -- Direct Relief, BD (Becton, Dickinson and Company) and the National Association of Free & Charitable Clinics (NAFC) today announced $125,000 in funding for...
Feb 20, 2020FRANKLIN LAKES, N.J., February 20, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD Synapsys™ microbiology...
Feb 17, 2020BD Kiestra™ ReadA is device listed with the U.S. FDAFRANKLIN LAKES, N.J., February 17, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the BD Kiestra™ ReadA is device...
Feb 13, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new, $6 million contract with the Fleming Fund, a U.K. aid program that helps low-...
-
Feb 12, 2020New capillary blood collection device combined with innovative sample handling and analytical technologies in clinical studies aim to make diagnostic blood testing more accessible and convenient
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term...
-
Feb 11, 2020
FRANKLIN LAKES, N.J. (Feb. 11, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of a 50-subject human clinical trial with...
Feb 6, 2020- As reported, revenues of $4.225 billion increased 1.6 percent.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for the first fiscal quarter ended December 31,...
-
Jan 29, 2020Three-year mortality and amputation data for Lutonix® 014 Drug-Coated Balloon Below-The-Knee IDE trial presented at LINC
FRANKLIN LAKES, N.J. (Jan. 29, 2020) – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that interim findings from the Lutonix below-the-knee...
-
Jan 27, 2020
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on March 31, 2020 to holders of record on March 10,...
-
Jan 23, 2020
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday,...
-
Jan 17, 2020
The meta-analysis published by Dr. Konstantinos Katsanos, et al in the Journal of Vascular and Interventional Radiology on January 14 focused on amputation-free survival (defined as freedom from...
-
Jan 9, 2020
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2020 earnings conference call on Thursday, February 6, 2020, at 8:00...
Jan 3, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday,...
Nov 25, 2019The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 cents per common share, an increase of 2.6 percent from the previous quarter....
-
Nov 22, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday,...
Nov 21, 2019New antimicrobial stewardship technology will be demonstrated at ASHP 2019 Midyear MeetingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating antimicrobial resistance (AMR) with new analytics...
-
Nov 18, 2019BD Kiestra™ IdentifA system is available in Europe (CE marked) and Canada
FRANKLIN LAKES, NJ (November 18, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) and...
-
Nov 15, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC") to purchase up to 500,000...
Nov 14, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies 2019 London Healthcare Conference on Thursday,...
Nov 12, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug...
-
Nov 5, 2019- As reported, full fiscal year revenues of $17.290 billion increased 8.2 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30,...
-
Oct 29, 2019
FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points...
-
Oct 28, 2019BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit is designed and tested to work with BD Rhapsody™ Single-Cell Analysis System, BD® AbSeq reagents and BD® Single-Cell Multiplexing Kit
Franklin Lakes, N.J., October 28, 2019 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the availability of BD Rhapsody WTA Amplification kit...
-
Oct 3, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday,...
-
Sep 28, 2019Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug...
Sep 26, 2019Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020,...
Aug 21, 2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Wells...
Aug 6, 2019- As reported, revenues of $4.350 billion increased 1.7 percent.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019....
-
Jul 23, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and...
-
Jul 22, 2019
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on...
-
Jul 18, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100...
-
Jul 2, 2019
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019, at 8:00 a.m....
-
Jun 20, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory...
-
Jun 4, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash, in the...
-
Jun 4, 2019Findings Based on Survey of 650 Health Care Professionals
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in...
-
Jun 3, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority...
-
May 31, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs 40th Annual Global Healthcare Conference on...
-
May 20, 2019
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the...
-
May 9, 2019- As reported, revenues of $4.195 billion decreased 0.6 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.195 billion for the second fiscal quarter ended March 31, 2019....
Apr 30, 2019New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S.BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™...
Apr 8, 2019BD BACTEC™ Platelet Quality Control Media is cleared by the U.S. Food and Drug Administration and CE-IVD marked for platelet testingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global availability of BD BACTEC™ platelet quality control media, which allows...
Mar 26, 2019BD FACSDuet(TM) system raises the bar on flow cytometry automation offering a fully integrated sample-to-answer solution with the BD FACSLyric(TM) clinical flow cytometerBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet(TM) automated flow cytometry system. The...
-
Mar 21, 2019
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to the recent letter from FDA to health care providers...
Mar 14, 2019Venovo(TM) Venous Stent proven safe and effective in iliac and femoral veinsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo(TM)...
-
Feb 13, 2019BD WavelinQ™ 4F EndoAVF System Receives 510(k) Clearance from U.S. Food and Drug Administration
FRANKLIN LAKES, N.J., February 13, 2019 –BD (Becton, Dickinson and Company), a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration for...
-
Feb 5, 2019- As reported, revenues of $4.160 billion increased 35.1 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31,...
-
Jan 24, 2019BD Nano(TM) Second Generation Pen Needle Receives 510(k) Clearance from U.S. Food and Drug Administration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the U.S. Food and Drug Administration 510(k) clearance of its second generation BD Nano(TM)...
-
Dec 20, 2018BD MAX(TM) Enteric Viral Panel Receives 510(k) Clearance from U.S. Food and Drug Administration
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX(TM) enteric viral...
Dec 11, 2018BD FACSLyric(TM) Flow Cytometer is First BD Product to Earn UL Cybersecurity Assurance Program CertificationBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL. This...
-
Nov 29, 2018Learn how advanced analytics can help combat a critical component of the opioid epidemic at the #ASHP18 Midyear Meeting
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems...
-
Nov 13, 2018Fully-automated BD Phoenix(TM) CPO Detect Test Receives U.S. FDA Clearance
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix(TM) CPO detect...
-
Nov 6, 2018- As reported, full fiscal year revenues of $15.983 billion increased 32.2 percent.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for the fourth fiscal quarter ended September 30,...
-
Oct 29, 2018
BD MedMined™ Surveillance Advisor has earned Meaningful Use Stage 3 (MU3) certification validating its ability to collect and properly report data around antimicrobial use and resistance data by...
-
Oct 23, 2018Brings Total Company Investment in Nebraska to $340 Million in Two Years
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to announce a $200 million...
Oct 17, 2018Company Joins Effort Alongside Rotary and Leading Global Health Organizations to Expand Vaccinations in IndiaBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a donation of 20 million syringes valued at $1 million to Rotary, a nonprofit...
-
Oct 16, 2018BD MAX(TM) MDR-TB Panel Obtains CE-IVD Status in Europe
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of the BD MAX(TM) MDR-TB panel in Europe. Clinicians can use the test...
-
Aug 28, 2018
BD (Becton, Dickinson and Company), Direct Relief, and the National Association of Community Health Centers (NACHC) recently awarded five community health centers with a total of $1 million in...
-
Aug 2, 2018
Click on the links below to view results for the 2018 third fiscal quarter: View document online PDF file of BD 2018 third fiscal quarter results About BD BD is one of the largest global medical...
Jul 26, 2018BD® AbSeq Assay Enables Deeper Understanding of Role Individual Cells Play in the Immune SystemBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD(®) AbSeq assay to analyze protein expression at the...
-
Jul 12, 2018
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that...
-
Jul 9, 2018everlinQ(TM) endoAVF System Receives FDA De Novo Marketing Authorization
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of TVA Medical, Inc., a company that develops...
-
Jun 27, 2018
Alexandria, VA., June 27, 2018 – In an effort to improve evidence-based care in Free and Charitable Clinics using point-of-care testing results, BD (Becton, Dickinson and Company) (NYSE: BDX) in...
-
Jun 18, 2018Visit BD Booth #9 and 10 to Learn how the Most Common Invasive Procedure doesn’t Need to be One of the Most Complex
Copenhagen, June 20, 2018 - During the 5th annual World Congress on Vascular Access (WoCoVA) being held June 20-22 in Copenhagen, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...
-
Jun 4, 2018BD Pyxis(TM) ES Refrigerator Expands Enterprise-wide Medication Management Solutions from BD to Improve Refrigerated Medication Management and Security
BD, Helmer Scientific Collaborate to Introduce First Fully Integrated Refrigerated Automated Dispensing Solution BD Pyxis(TM) ES Refrigerator Expands Enterprise-wide Medication Management...
-
May 3, 2018
Click on the links below to view results for the 2018 second fiscal quarter: View document online PDF file of BD 2018 second fiscal quarter results About BD BD is one of the largest global medical...
-
Apr 27, 2018Alberto Mas to Lead Medical Segment;
BD Names Three Executives to Segment Leadership Roles Alberto Mas to Lead Medical Segment; Patrick Kaltenbach to Lead Life Sciences Segment; Bill Tozzi to Lead Interventional Segment on Interim Basis
Apr 26, 2018New Cell Sorter Extends BD's Robust Portfolio of Flow Cytometry Research SolutionsBD Launches BD FACSymphony(TM) S6 High Parameter Cell Sorter to Enable Sorting of Rare Cell Types New Cell Sorter Extends BD's Robust Portfolio of Flow Cytometry Research Solutions FRANKLIN LAKES,...
Apr 19, 2018BD Synapsys(TM) Microbiology Informatics Solution Among New Offerings Shown at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)BD Unveils Suite of Diagnostic Informatics and Automation Innovations BD Synapsys(TM) Microbiology Informatics Solution Among New Offerings Shown at European Congress of Clinical Microbiology and...
-
Mar 22, 2018
BD Updates Instructions for Use for Certain BD Vacutainer® Blood Collection Tubes FRANKLIN LAKES, N.J., March 22, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading...
-
Mar 5, 2018New BD Survey Conducted by HIMSS Analytics® Reveals Heightened Need for Seamless Integration of Disparate Technologies during Medication Transit
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will demonstrate its comprehensive approach to integrated, enterprise medication management to help...
-
Feb 20, 2018CE-IVD labeled PAXgene® Blood ccfDNA tube will be available in Western Europe
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial availability of the CE-IVD marked PAXgene(®) Blood ccfDNA tube within...
-
Feb 13, 2018The BD Onclarity(TM) HPV Assay can detect 14 high-risk HPV types and provide additional information to guide physician decision-making
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pre-market approval from the U.S. Food and Drug Administration...
-
Feb 6, 2018
Click on the links below to view results for the 2018 first fiscal quarter: View document online PDF file of BD 2018 first fiscal quarter results About BD BD is one of the largest global medical...
-
Feb 6, 2018- As reported, revenues of $3.080 billion increased 5.4 percent, or 3.7 percent on a currency-neutral basis, which includes an estimated 110 basis point adverse impact from the previously disclosed change in the U.S. dispensing business model.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.080 billion for the first fiscal quarter ended December 31,...
-
Jan 15, 2018New Test Provides Diagnostic Results Up to 10 Times Faster Than Traditional Tests
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a...
-
Jan 12, 2018
BD (Becton, Dickinson and Company) (NYSE: BDX) issued the following statement in response to receiving a warning letter from the U.S. Food and Drug Administration for its Preanalytical Systems...
-
Dec 29, 2017
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR), creating a new health...
-
Dec 28, 2017
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance by the Ministry of Commerce of the People's...
-
Dec 22, 2017
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance by the U.S. Federal Trade Commission (FTC)...
-
Dec 11, 2017
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has established a Product Security Partnership Program that emphasizes collaboration...
-
Dec 4, 2017Experience the Advantage of Complete Medication Management at #ASHP17 BD Booth 721
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today revealed several technology innovations to further optimize the entire medication management...
-
Nov 16, 2017New BD HealthSight(TM) Platform for Enterprise Medication Management Takes System-Wide Approach to Make Medication Management Safer, Simpler and Smarter
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight(TM) platform...
-
Nov 16, 2017
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's announcement by Merit Medical Systems, Inc. that it...
-
Nov 2, 2017
Click on the links below to view results for the 2017 fourth fiscal quarter and full year: View document online PDF file of BD 2017 fourth fiscal quarter and full year results About BD BD is one...
-
Oct 26, 2017
Mississauga, Ontario, Oct. 26, 2017 – In recognition of Canadian Patient Safety Week (CPSW), occurring Oct. 30 – Nov.3, BD (Becton, Dickinson and Company), a leading global medical technology...
Oct 25, 2017Company Also Celebrates 50 Years of Cannula Production in ColumbusBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to break ground on a $60...
-
Sep 28, 2017
Mississauga, Ontario and Hamilton, Ontario - September 28, 2017 – BD (Becton, Dickinson and Company), a leading global medical technology company and the Canadian Society for Medical Laboratory...
-
Sep 26, 2017Fully-automated BD Phoenix(TM) CPO detect test helps detect dangerous pathogens
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch(1) of the first automated phenotypic test to detect and classify...
-
Sep 20, 2017New Molecular Assays Will be for Use on the BD MAX(TM) System
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Euroclone (Euroclone Diagnostica Srl) today announced a development and global distribution...
Sep 19, 2017BD Ultra-Fine(TM) Micro 6mm Pen Needles Now AvailableBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the introduction of the BD Ultra-Fine(TM) micro pen needle 6mm x 32G for use with...
Sep 12, 2017BD Rhapsody(TM) single cell analysis system launches for gene expression profiling, plans to expand for protein analysisBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of BD Rhapsody, a platform for single cell analysis with the ability to...
-
Aug 28, 2017
SAN DIEGO, Aug. 28, 2017 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, Direct Relief and the National Association of Community Health Centers...
-
Aug 14, 2017
FRANKLIN LAKES, N.J., August 14, 2017 – BD (Becton, Dickinson and Company), a leading global medical technology company, has obtained 510(k) clearance from the U.S. Food and Drug Administration...
-
Aug 3, 2017
Click on the links below to view results for 2017 Third Fiscal Quarter: View Document Online PDF File of BD 2017 Third Fiscal Quarter Results About BD BD is one of the largest global medical...
Jul 19, 2017BD FACSLyric(TM) Flow Cytometer System with BD Multitest(TM) Assays Offers Reliability and ConsistencyBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)...
-
Jul 18, 2017New BD Kiestra(TM) Urine Culture App1 Drives Increased Lab Efficiency and Impacts Patient Management
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new technology that can automatically report and release negative urine cultures. Every...
-
Jun 20, 2017New Micro-Laparoscopic Instruments Offer Surgeons Less Invasive Option for Patients
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its new line of Snowden-Pencer((TM)) 3.0mm laparoscopic ergonomic take-apart...
-
Jun 13, 2017Leaders in flow cytometry tools collaborate to deliver cloud data management capabilities and streamline experimental execution
ASHLAND, Ore and FRANKLIN LAKES, N.J., June 13, 2017 ─ FlowJo, LLC, a life science informatics and data analysis company with 20 years of experience in software for analyzing single-cell data,...
-
Jun 6, 2017
FRANKLIN LAKES, N.J., June 6, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2016 Sustainability Report. BD’s...
-
Jun 5, 2017Extends BD MAX(TM) Enteric Panel Portfolio with latest Molecular Test that Targets Infectious Diarrhea
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its newly developed molecular test for detecting harmful intestinal bacteria...